ADIAL PHARMACEUTICALS INC (ADIL) Stock Income Statement
NASDAQ:ADIL - Nasdaq - US00688A2050 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 8.71M | 8.28M | 6.89M | 13.32M | 17.74M | |||
| Research and Development | 3.52M | 3.23M | 1.27M | 4.18M | 8.40M | |||
| Selling, General, and Administrative Expenses | 5.18M | 5.06M | 5.62M | 9.14M | 9.34M | |||
| Operating Income | -8.71M | -8.28M | -6.89M | -13.32M | -17.74M | |||
| Interest Income/Expense | -334.20K | -373.50K | -124.10K | 60.00K | 10.00K | |||
| Other Income/Expense | 91.20K | -4.54M | 10.20K | 520.00K | -260.00K | |||
| Non Recurring Items | N/A | N/A | N/A | 0.00 | -1.52M | |||
| Income Before Taxes | -8.95M | -13.20M | -7.00M | -12.73M | -19.52M | |||
| Income Tax | N/A | 0.00 | 0.00 | 0.00 | -90.00K | |||
| Net Income | -8.95M | -13.20M | -5.12M | -12.73M | -19.42M | |||
| EBITDA | -8.71M | -8.28M | -6.89M | -13.31M | -17.73M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.63 | -2.72 | -3.59 | -12.71 | -26.24 | |||
| Non GAAP EPS | -1.63 | -1.91 | -4.32 | -13.00 | N/A | |||
| Statistics | ||||||||
All data in USD